Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia

Bone Marrow Transplantation

Volumn 22, Issue 1, 1998, Pages 47-51

  Tomas J F ^a,b   Lopez Lorenzo J L ^a   Requena, M J ^a   Aguilar, R ^a   Steegmann, J L ^a   Camara R ^a   Alegre, A ^a   Arranz, R ^a   Figuera, A ^a   Fernandez Ranada J M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Allogeneic; BMT; CML; Interferon

Indexed keywords

ALPHA INTERFERON; INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPHIL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 2642680046     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701288     Document Type: Article

References (27)

1. Kantarjian H, O'Brien S, Anderlini P, Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 1996; 87: 3069-3081.
2. Anasetti C, Howe C, Petersdorf E et al. Marrow transplants from HLA-matched unrelated donors: an NMDP update and the Seattle experience. Bone Marrow Transplant 1994; 13: 214-258.
3. Clift R. Appelbaum FR, Thomas ED. Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954-1956.
4. Moreb J, Johnson T, Kubilis P et al. Improved survival of patients with chronic myelogenous leukemia undergoing allogeneic bone marrow transplantation. Am J Hematol 1995; 50: 304-306.
5. Bortin M, Horowitz MM, Rowlings PA et al. 1993 Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12: 97-104.
6. Gratwohl A, Hermans J, Niederwieser D et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993; 12: 509-516.
7. Carella A, Frassoni F, Melo J et al. New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 1997; 82: 478-495.
8. Bacigalupo A, Gualandi F, Van Lint MT et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transplant 1993; 12: 443-448.
9. Devergie A, Blaisse D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxantotal body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood 1995; 85: 2263-2268.
10. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-a with busulfan and hydroyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994; 84: 4064-4077.
11. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
12. Allan N, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukemia. Lancet 1995; 345: 1392-1397.
13. Schmidt H, Kellermann-Kegreiss E, Steiert Y et al Differential regulation of human leukocyte antigen class I genes by interferon in vivo and in vitro. J Immunother 1993; 14: 169-174.
14. Cottler-Fox M, Torrisi J, Spitzer TR, Deeg HJ. Increased toxicity in total body irradiation in patients receiving interferon for leukemia. Lancet 1990; 328: 174-175.
15. Santucci M, Solsigo D, Pileri S et al. Interferon-alpha effects on stromal compartment of normal and chronic myeloid leukemia hematopoiesis. Leuk Lymphoma 1993; 11 (Suppl. 1): 113-117.
16. Giralt S, Kantarjian HM, Talpaz M et al. Effect of prior interferon alpha therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1993; 11: 1055-1061.
17. Beelen D, Graeven U, Elmaagach AH et al. Prolonged administration of interferon alpha in patients with chronic phase Philadelphia chromosome positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981-2990.
18. Fernández-Rañada J, Lavilla E, Odriozola J et al. Interferon alpha 2a in the treatment of chronic myelogenous leukemia in chronic phase. Results of Spanish Group on interferon alpha 2a in CML. Leuk Lymphoma 1993; 11 (Suppl. 1): 175-179.
19. Tomás JF, Gómez-Garća de Soria, López-Lorenzo JL et al. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission. Importance of duration of first complete remission in final outcome. Bone Morrow Transplant 1996; 17: 979-984.
20. Deeg HJ. Treatment of human acute graft-versus-host disease with antithymocyte globulin and corticosteroids. Transplantation 1985; 40: 162-166.
21. Hervé P. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin 2 monoclonal antibody (B-B10). Blood 1990; 75: 1017-1023.
22. McDonald G. Venoocclusive disease of the liver after marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116-122.
23. Tomás JF, Cásado LF, Cámara R et al. Decreased early mortality for patients with CML in first chronic phase undergoing allogeneic BMT (abstract). Br J Haematol 1996; 93 (Suppl. 2): 259-260.
24. Goldman JM, Szydo R, Horowitz MM et al. Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235-2238.
25. McGlave P, Kollman C, Shu XO et al. The first 1000 unrelated donor transplants for CML: lessons from the National Marrow Donor Program (NMDP). Blood 1996; 88 (Suppl. 1): 483a.
26. Shepherd P, Richards S, Allan N. Survival after allogeneic bone marrow transplantation (BMT) in patients randomised into a trial of IFN-alpha versus chemotherapy: no significant adverse effect of prolonged IFN-alpha administration. Blood 1995; 86 (Suppl. 1): 94a.
27. Bearman S, Mori M, Beatty PG et al. Comparison of morbidity and mortality after marrow transplantation from HLA-genotypically identical siblings and HLA-phenotypically identical unrelated donors. Bone Marrow Transplant 1994; 13: 31-35.